Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 544

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1B
Chunk 544
---
2021 when he founded Locate Venture Corp. in September 2021.  Locate Venture is a strategy and investment
consulting firm focused on advancing and supporting early-stage biotech startups. Prior to founding Locate Venture Corp., from February
2015 to September 2020, Mr. Aminov served as the President of Finds4less Inc., a global distributor of electronics and gaming products.
In this role, Mr. Aminov provided strategic oversight and direction for all aspects of the company’s operations, while also spearheading
new business development initiatives to capitalize on emerging market opportunities. Mr. Aminov’s more than two decades of experience
includes experience with the biotech industry’s particular challenges, including creating strategic alliances and guiding startups
toward growth and prosperity. Mr. Aminov earned a B.A. in Accounting from Touro University in New York. We believe that Mr. Aminov is
qualified to serve as one of our directors based on his finance and investment experience, particularly with early stage life sciences
companies.

Michelle
Yanez, MBA has served as our Chief Financial Officer since June 2024, and also currently serves as the Chief Financial Officer
of MIRA Pharmaceuticals. Ms. Yanez is a senior financial executive with over 25 years of experience in public and privately held biotech,
pharmaceutical, and life science companies. Ms. Yanez’ experience includes a broad range of responsibilities in a highly complex
and regulated market. She also brings deep corporate governance experience through her work with corporate boards, including audit and
finance committees. From May 2002 until its acquisition in April 2022, Ms. Yanez held various leadership positions at BioDelivery Sciences
International, Inc. (Nasdaq: BDSI). In her role, she led financial offerings, managed due diligence for product acquisitions and financings
and managed finance documents and filings for the tender offer, leading to the acquisition of BioDelivery Sciences in April 2022. Ms.
Yanez also serves as a non-employee director of Inhibitor Therapeutics, Inc. (OTCQB: INTI), a publicly traded pharmaceutical development
company focused on therapeutics for certain cancers and non-cancerous proliferation disorders, since December 2022. Ms. Yanez is also
Co-Founder and Chief Financial Officer of Santander Pharma Consulting, a privately held life sciences consulting firm that provides business
development and commercial strategy services to pharmaceutical, medical devices, and life science